Literature DB >> 29182008

Aberrant expression of PlncRNA-1 and TUG1: potential biomarkers for gastric cancer diagnosis and clinically monitoring cancer progression.

Zohreh Baratieh1, Zahra Khalaj1, Mohammad Amin Honardoost1,2, Modjtaba Emadi-Baygi3,4, Hossein Khanahmad1, Mansoor Salehi1, Parvaneh Nikpour1,5.   

Abstract

AIM: To evaluate PlncRNA-1, TUG1 and FAM83H-AS1 gene expression and their possible role as a biomarker in gastric cancer (GC) progression. PATIENTS &
METHODS: Long noncoding RNA expressions and clinicopathological characteristics were assessed in 70 paired GC tissues. Furthermore, corresponding data from 318 GC patients were downloaded from The Cancer Genome Atlas database.
RESULTS: Expression of PlncRNA-1 and TUG1 were significantly upregulated in GC tumoral tissues, and significantly correlated with clinicopathological characters. However, FAM83H-AS1 showed no consistently differential expression. The expression of these three long noncoding RNAs was significantly higher in The Cancer Genome Atlas tumoral tissues.
CONCLUSION: In conclusion, PlncRNA-1 and TUG1 genes may play a critical role in GC progression and may serve as potential diagnostic biomarkers in GC patients.

Entities:  

Keywords:  FAM83H-AS1; PlncRNA-1; TUG1; gastric cancer; gene expression

Mesh:

Substances:

Year:  2017        PMID: 29182008     DOI: 10.2217/bmm-2017-0090

Source DB:  PubMed          Journal:  Biomark Med        ISSN: 1752-0363            Impact factor:   2.851


  15 in total

Review 1.  Emerging role of lncRNAs in the normal and diseased intestinal barrier.

Authors:  Jie Chen; Jianhua Wan; Jianfang Ye; Liang Xia; Nonghua Lu
Journal:  Inflamm Res       Date:  2018-07-14       Impact factor: 4.575

Review 2.  Role of taurine, its haloamines and its lncRNA TUG1 in both inflammation and cancer progression. On the road to therapeutics? (Review).

Authors:  Stella Baliou; Anthony M Kyriakopoulos; Demetrios A Spandidos; Vassilios Zoumpourlis
Journal:  Int J Oncol       Date:  2020-07-14       Impact factor: 5.650

3.  Long non-coding RNA TUG1 promotes osteosarcoma cell proliferation and invasion through inhibition of microRNA-212-3p expression.

Authors:  Heng Li; Guofeng Tian; Feipeng Tian; Lin Shao
Journal:  Exp Ther Med       Date:  2018-05-24       Impact factor: 2.447

4.  Comment on "circSMARCA5 Functions as a Diagnostic and Prognostic Biomarker for Gastric Cancer".

Authors:  Farid Rahimi; Amin Talebi Bezmin Abadi
Journal:  Dis Markers       Date:  2019-09-12       Impact factor: 3.434

Review 5.  Molecular mechanisms of TUG1 in the proliferation, apoptosis, migration and invasion of cancer cells.

Authors:  Hui Zhou; Lina Sun; Fusheng Wan
Journal:  Oncol Lett       Date:  2019-09-10       Impact factor: 2.967

Review 6.  The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis.

Authors:  Qin Yang; Jie Wang; Pingyong Zhong; Tinggang Mou; Hao Hua; Pan Liu; Fei Xie
Journal:  Cancer Cell Int       Date:  2020-03-06       Impact factor: 5.722

7.  LncRNA CBR3-AS1 regulates of breast cancer drug sensitivity as a competing endogenous RNA through the JNK1/MEK4-mediated MAPK signal pathway.

Authors:  Ming Zhang; Yan Wang; Longyang Jiang; Xinyue Song; Ang Zheng; Hua Gao; Minjie Wei; Lin Zhao
Journal:  J Exp Clin Cancer Res       Date:  2021-01-25

8.  Novel lncRNA LINC00941 Promotes Proliferation and Invasion of Colon Cancer Through Activation of MYC.

Authors:  Lin Chang; Dongmin Zhou; Suxia Luo
Journal:  Onco Targets Ther       Date:  2021-02-22       Impact factor: 4.147

9.  LncRNA Taurine Upregulated Gene 1 as a Potential Biomarker in the Clinicopathology and Prognosis of Multiple Malignant Tumors: A Meta-Analysis.

Authors:  Qi Huang; Jingjing Wu; Hui Wang; Na Li; Zhen Yang; Mingjun Zhang
Journal:  Dis Markers       Date:  2021-03-02       Impact factor: 3.434

Review 10.  Long non-coding RNAs as the critical factors during tumor progressions among Iranian population: an overview.

Authors:  Zahra Rahmani; Majid Mojarrad; Meysam Moghbeli
Journal:  Cell Biosci       Date:  2020-01-14       Impact factor: 7.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.